Literature DB >> 25643693

Vaccine design via nonnegative lasso-based variable selection.

Zonghui Hu1, Dean A Follmann, Kazutoyo Miura.   

Abstract

There are many different strains of malaria parasites, each represented by a unique sequence of amino acids. A desirable vaccine would match the amino acid sequence of the parasite antigen. Because of the three-dimensional structure of protein, not all sites in the amino acid sequence participate in the binding between the vaccine-induced antibody and the parasite antigen. Nor do all sites have equal importance. In this work, we apply a nonnegative lasso-based variable selection to identify the 'important' amino acid sites and evaluate their relative importance. We then define a metric, the functional coverage, to measure the 'effective' matching in the amino acid sequence between the vaccine and the parasite. With the variable selection procedure, development of a vaccine needs only to target the important sites, and the potential effectiveness of a vaccine candidate is reflected by the functional coverage. Published 2015. This article is a U.S. Government work and is in the public domain in the USA. Published 2015. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  amino acid sequence; malaria vaccine; nonnegative lasso regression; seemingly independent screening

Mesh:

Substances:

Year:  2015        PMID: 25643693      PMCID: PMC4390489          DOI: 10.1002/sim.6452

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  9 in total

1.  Structural basis of antigenic escape of a malaria vaccine candidate.

Authors:  Sheetij Dutta; Seung Yeon Lee; Adrian H Batchelor; David E Lanar
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-16       Impact factor: 11.205

2.  Discussion of "Sure Independence Screening for Ultra-High Dimensional Feature Space.

Authors:  Hao Helen Zhang
Journal:  J R Stat Soc Series B Stat Methodol       Date:  2008-11       Impact factor: 4.488

3.  Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: implications for vaccine design.

Authors:  Junhui Duan; Jianbing Mu; Mahamadou Ali Thera; Deirdre Joy; Sergei L Kosakovsky Pond; David Diemert; Carole Long; Hong Zhou; Kazutoyo Miura; Amed Ouattara; Amagana Dolo; Ogobara Doumbo; Xin-Zhuan Su; Louis Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-30       Impact factor: 11.205

4.  Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria.

Authors:  Prakash Srinivasan; Emmanuel Ekanem; Ababacar Diouf; Michelle L Tonkin; Kazutoyo Miura; Martin J Boulanger; Carole A Long; David L Narum; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-23       Impact factor: 11.205

5.  A field trial to assess a blood-stage malaria vaccine.

Authors:  Mahamadou A Thera; Ogobara K Doumbo; Drissa Coulibaly; Matthew B Laurens; Amed Ouattara; Abdoulaye K Kone; Ando B Guindo; Karim Traore; Idrissa Traore; Bourema Kouriba; Dapa A Diallo; Issa Diarra; Modibo Daou; Amagana Dolo; Youssouf Tolo; Mahamadou S Sissoko; Amadou Niangaly; Mady Sissoko; Shannon Takala-Harrison; Kirsten E Lyke; Yukun Wu; William C Blackwelder; Olivier Godeaux; Johan Vekemans; Marie-Claude Dubois; W Ripley Ballou; Joe Cohen; Darby Thompson; Tina Dube; Lorraine Soisson; Carter L Diggs; Brent House; David E Lanar; Sheetij Dutta; D Gray Heppner; Christopher V Plowe
Journal:  N Engl J Med       Date:  2011-09-15       Impact factor: 91.245

6.  Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.

Authors:  Elissa M Malkin; David J Diemert; Julie H McArthur; John R Perreault; Aaron P Miles; Birgitte K Giersing; Gregory E Mullen; Andrew Orcutt; Olga Muratova; May Awkal; Hong Zhou; Jin Wang; Anthony Stowers; Carole A Long; Siddhartha Mahanty; Louis H Miller; Allan Saul; Anna P Durbin
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

7.  Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Authors:  Kazutoyo Miura; Raul Herrera; Ababacar Diouf; Hong Zhou; Jianbing Mu; Zonghui Hu; Nicholas J MacDonald; Karine Reiter; Vu Nguyen; Richard L Shimp; Kavita Singh; David L Narum; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2013-02-19       Impact factor: 3.441

8.  Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT™ and Montanide ISA 51 in rhesus macaques.

Authors:  Kwadwo A Kusi; Edmond J Remarque; Vanessa Riasat; Vanessa Walraven; Alan W Thomas; Bart W Faber; Clemens H M Kocken
Journal:  Malar J       Date:  2011-07-04       Impact factor: 2.979

9.  Defining the antigenic diversity of Plasmodium falciparum apical membrane antigen 1 and the requirements for a multi-allele vaccine against malaria.

Authors:  Damien R Drew; Anthony N Hodder; Danny W Wilson; Michael Foley; Ivo Mueller; Peter M Siba; Arlene E Dent; Alan F Cowman; James G Beeson
Journal:  PLoS One       Date:  2012-12-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.